Nicholas Botwood Increases Stake in Syndax Pharmaceuticals

Nicholas Botwood, Syndax's Head of R&D, purchased over 22,000 shares.

Written by Trueearnings · Published Jun 14, 2026, 2:00 AM EDT · Updated Jun 14, 2026, 8:00 PM EDT

Key Points

Nicholas Botwood, Head of R&D at Syndax Pharmaceuticals, bought 22,515 shares on June 11, 2026, at $13.82 each.
Syndax Pharmaceuticals trades on NasdaqGS with a market cap of $1.62 billion and a 52-week range of $8.59 to $25.59.
Analysts remain bullish on Syndax with a consensus strong buy rating and a mean price target of $39.00.

On June 11, 2026, Nicholas Botwood, the Head of Research and Development and Chief Medical Officer at Syndax Pharmaceuticals, Inc. (NasdaqGS: SNDX), purchased 22,515 shares of the company. The shares were bought at an average price of $13.82 each, amounting to a total transaction value of approximately $311,157. This purchase was not part of a pre-arranged trading plan.

Insider Buying and Selling at Syndax Pharmaceuticals, Inc.

Nicholas Botwood made several transactions around this period. On June 12, 2026, he executed planned sales and additional buys, reflecting a dynamic approach to managing his holdings in the company. The purchases on June 11 and 12 highlight his continued interest in the company's prospects.

Other Institutional Activity in Syndax Pharmaceuticals

In other institutional activity, BlackRock, Inc. increased its holdings by 15,424 shares, ending with 8,254,426 shares valued at about $192.8 million. Meanwhile, Goldman Sachs Group Inc. reduced its position, selling 698,588 shares to hold 4,996,787 shares worth approximately $116.7 million. Vanguard Capital Management LLC made a notable move by acquiring 3,822,579 shares, now holding shares valued at $89.3 million.

Syndax Pharmaceuticals Stock Snapshot

Shares of Syndax Pharmaceuticals are trading near $18.26. The company has a market capitalization of approximately $1.62 billion. Although it is not currently profitable, it has a forward P/E ratio of -33.50. The stock has seen a 52-week low of $8.59 and a high of $25.59, with a 50-day moving average of $20.93 and a 200-day moving average of $19.45. Syndax maintains a strong liquidity position with a current ratio of 5.47 and a quick ratio of 4.90, though it carries a high debt-to-equity ratio of 829.75.

Recent Earnings

Syndax reported revenue of $217.17 million, with a modest growth rate of 2.24%. Despite a negative net margin of -112.01% and a return on equity of -189.53%, the company continues to focus on its pipeline development. The next earnings report is expected on August 3, 2026.

Analysts Set New Price Targets

Analysts are optimistic about Syndax, as reflected in recent ratings. On May 22, 2026, HC Wainwright & Co. reiterated their buy rating with a $40 price target. UBS and Barclays both maintained buy ratings with targets of $37. The consensus among 12 analysts is a strong buy, with a mean target price of $39.00.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company based in New York, New York. It focuses on developing therapies for cancer treatment. The company's lead products include Revuforj, a menin inhibitor for acute leukemia, and Niktimvo, a receptor-blocking antibody for chronic graft-versus-host disease. Syndax also explores treatments for acute myeloid leukemia and idiopathic pulmonary fibrosis. Founded in 2005, the company is led by CEO Michael A. Metzger.

Bottom Line

Nicholas Botwood's recent purchase of Syndax shares underscores his confidence in the company's future. With a robust pipeline and ongoing developments in cancer therapies, Syndax remains a key player in the biotechnology sector. Investors and analysts continue to watch the company closely, especially given its strategic initiatives and upcoming earnings release. As always, insider transactions provide a glimpse into management's perspective on the company's value, but they reflect past actions and may not indicate future performance.